NPPA and cardiac hypertrophy: SARS-CoV-2 Nsp6 (Nsp6-OE) significantly increased Atrial natriuretic peptide (ANP) and type B natriuretic peptide (BNP)—both established markers of cardiac hypertrophy—compared to primary cardiomyocytes from the control group (Lipofectamine; Lipo) (Fig. 6b, c).